| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — |
| 29 Jun 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
A. This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,” is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), by providing... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — |
| 04 May 2026 |
8-K: Regulation FD Disclosure
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— |
| 23 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
The accompanying notes are an integral part of these condensed consolidated financial statements. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
Effective January 9, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO® (berotralstat) in the United States from $44,484.33 per 28-day pack (of either 15... |
| 12 Dec 2025 |
8-K: Other Events
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years |
| 11 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 9, 2025, Nancy J. Hutson, Ph.D. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of her intention to retire from the Board of Directors of the Company (the “Board”), effective as of the earlier of (i) the closing date ... |
| 03 Dec 2025 |
8-K: Other Events
RESEARCH TRIANGLE PARK, N.C. – December 3, 2025 – BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
—Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— |
| 14 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Form of Certificate of Incorporation of the Surviving Corporation |
| 01 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This GLOBAL BRAND AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 1, 2025 (the “Effective Date”), is entered into by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Seller”) and BioCryst Ireland Lim... |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 6, 2025, Dr. Helen Thackray, Chief Research and Development Officer of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), notified the Company of her intention to resign from her role as Chief Research and ... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
—Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— |
| 31 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his inte... |
| 07 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. |
Loading...